BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 48,520 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 48,520 shares of the business’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00. Following the sale, the chief executive officer directly owned 11,698 shares of the company’s stock, valued at $3,560,286.30. This represents a 80.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Trading Up 0.9%

Shares of ONC opened at $306.56 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a 50 day simple moving average of $290.24 and a two-hundred day simple moving average of $308.90. The firm has a market cap of $33.64 billion, a P/E ratio of 68.58 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. On average, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on ONC shares. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd. Leerink Partners increased their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Wolfe Research initiated coverage on shares of BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price for the company. Barclays cut their target price on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Guggenheim upped their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $390.92.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after purchasing an additional 97,244 shares during the period. Slow Capital Inc. grew its position in shares of BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after buying an additional 9,280 shares in the last quarter. Capital International Sarl increased its stake in shares of BeOne Medicines by 2.7% during the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after buying an additional 3,956 shares during the period. Capital International Investors increased its stake in shares of BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after buying an additional 67,808 shares during the period. Finally, AIA Group Ltd raised its holdings in shares of BeOne Medicines by 31.4% in the third quarter. AIA Group Ltd now owns 32,303 shares of the company’s stock valued at $11,006,000 after acquiring an additional 7,716 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.